Cantel Medical Corporation
150 Clove Road, 9th Floor
Little Falls
New Jersey
07424-2139
United States
Tel: 973-890-7220
Fax: 973-890-7270
Website: http://www.cantelmedical.com/
264 articles about Cantel Medical Corporation
-
Cantel Medical LLC Announces a One-Day Extension of Its Offer to Purchase Relating to Outstanding Convertible Senior Notes
6/29/2021
Cantel Medical LLC announced that it has extended the Fundamental Change Expiration Date for its previously announced tender offer outlined in the Offer to Purchase and Notice of Fundamental Change, Make-Whole Fundamental Change, Settlement Method and Entry into Supplemental Indenture to Holders of 3.25% Convertible Senior Notes Due 2025 dated June 3, 2021.
-
Cantel Medical LLC Announces Offer to Purchase Relating to Outstanding Convertible Senior Notes, Fundamental Change and Make-Whole Fundamental Change
6/3/2021
Cantel Medical LLC, formerly known as Cantel Medical Corp., announced that it has delivered a notice to holders of its 3.25% Convertible Senior Notes due 2025, pursuant to the indenture governing the Notes, notifying holders that, as a result of each of the consummation of the series of mergers contemplated by the Agreement and Plan of Merger, dated as of January 12, 2021
-
Cantel Medical Reports Strong Financial Results for its Second Quarter Fiscal Year 2021
3/9/2021
Demand for Medical and Dental IP&C solutions continue to outpace elective procedure volume Strong recurring revenue mix and continued cost discipline driving higher profitability - Net sales of $294.0M, up 1.9% - GAAP diluted EPS of $0.27, up $0.32 versus prior year - Non-GAAP diluted EPS of $0.79, up 29.5% - GAAP net income of $12.1M, up $14.3M versus prior year
-
STERIS Announces Definitive Agreement to Acquire Cantel Medical
1/12/2021
Complementary to STERIS’s product and service portfolio, focused on infection prevention Extends STERIS’s reach to Dental Customers $110 million in expected EBIT synergies by year four Accretive to adjusted earnings per diluted share in year one Conference call with STERIS and Cantel management today at 8:00 a.m. ET
-
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2021
12/8/2020
Strong execution in Medical and Dental drives record financial results - Demand for infection prevention products continues to accelerate - Strong recurring revenue mix and cost discipline driving increased profitability - Hu-Friedy synergies well ahead of schedule - Net sales of $297.0M, up 15.5% - GAAP diluted EPS of $0.57, up 307.1% - Non-GAAP diluted EPS of $0.90, up 38.5% - GAAP net income of $24.5M, up 324.2%
-
Censis Technologies and Cantel Medical Enter Into Partnership to Develop Differentiated Endoscope Reprocessing Software Solution
12/7/2020
Companies combining their key strengths to provide enhanced integrated workflow software solution designed to provide superior infection prevention and practice optimization
-
Cantel Medical and Censis Technologies Enter into Partnership to Develop Differentiated Endoscope Reprocessing Software Solution
12/7/2020
Companies combining their key strengths to provide enhanced integrated workflow software solution designed to provide superior infection prevention and practice optimization
-
Cantel Announces Senior Leadership Promotions in Dental
12/3/2020
CANTEL MEDICAL CORP. announced the appointment of Andy Xilas to President, Cantel Dental effective January 1, 2021.
-
Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2020
11/24/2020
CANTEL MEDICAL CORP . (NYSE:CMD) will release the results for its first quarter ended October 31, 2020 on Tuesday, December 8, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET .
-
Cantel Pre-Announces Estimated Revenue for the 1st Quarter 2020
10/22/2020
CANTEL MEDICAL CORP. announced an estimated revenue range for the company's first fiscal quarter, ending on October 31st, 2020, of $290 - $295 million, an increase of approximately 25% sequentially from the prior quarter, a year over year increase of approximately 14% on a reported basis and a decrease of approximately 3% on an organic basis.
-
Cantel Hires Michael Drexel to SVP and Chief Technology Officer
10/1/2020
CANTEL MEDICAL CORP announced that Michael Drexel has been hired as Senior Vice President and Chief Technology Officer reporting to George Fotiades, Chief Executive Officer.
-
Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2020
9/17/2020
Medical and Dental well positioned as elective procedures positively rebound - COVID fourth quarter impact on elective procedures less severe than expected - Elective procedures rebounded to approximately 80% - 85% of pre-COVID levels and strengthening - Net sales of $233.4M, down 2.5% - GAAP diluted EPS of $(0.05), down 125.5% - Non-GAAP diluted EPS of $0.24, down 62.6% - GAAP net loss of $(2.3)M, down 125.6% - Non-GAAP net i
-
Cantel Medical Corp. to Hold Conference Call to Discuss Results for its Fourth Quarter Ended July 31, 2020
9/3/2020
CANTEL MEDICAL CORP. will release the results for its fourth quarter ended July 31, 2020 on Thursday, September 17, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.
-
Cantel Pre-Announces Estimated Revenue for the 4th Quarter
8/6/2020
CANTEL MEDICAL CORP. announced an estimated revenue range for the company's fiscal fourth quarter, which ended July 31st, 2020.
-
Cantel Promotes Peter Clifford to President
8/3/2020
CANTEL MEDICAL CORP. announced that Peter Clifford, currently Executive Vice President and Chief Operating Officer, has been promoted to President and Chief Operating Officer.
-
Cantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2020
6/4/2020
Cantel Medical Corp. announced financial results for its third quarter ended April 30, 2020.
-
Cantel Announces Full Exercise of Option by Initial Purchasers to Purchase Additional Convertible Senior Notes
5/22/2020
CANTEL MEDICAL CORP. (NYSE:CMD) ("Cantel" or the "Company") today announced the sale of $28 million in aggregate principal amount of its 3.25% convertible senior notes due 2025 in respect of the Company's previously announced private offering of the notes to persons reasonably believed to be qualified institutional buyers pursua
-
Cantel Medical Corp. to Hold Conference Call to Discuss Results for its Third Quarter Ended April 30, 2020
5/21/2020
CANTEL MEDICAL CORP. will release the results for its third quarter ended April 30, 2020 on Thursday, June 4, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.
-
Cantel Announces Pricing of $140 Million Private Offering of Convertible Senior Notes Due 2025
5/13/2020
CANTEL MEDICAL CORP. (NYSE: CMD) ("Cantel" or the "Company") today announced the pricing of its offering of $140 million aggregate principal amount of 3.25% convertible senior notes due 2025 (the "Notes") in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A un
-
Cantel Announces Proposed Private Offering of Convertible Senior Notes Due 2025
5/12/2020
CANTEL MEDICAL CORP . (NYSE: CMD) ("Cantel" or the "Company") today announced its intention to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private offering only to persons reasonably believed to be qualified institutional buyers pur